Adjuvant Combination for Kidney Cancer Gets FDA's Blessing

(MedPage Today) -- The FDA on Friday approved belzutifan (Welireg) plus pembrolizumab (Keytruda, Keytruda Qlex) as adjuvant therapy for renal cell carcinoma (RCC) with a clear cell component.
Based on results from LITESPARK-022, the combination...